Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Kamada Ltd (KMDA)

Kamada Ltd (KMDA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 242,189
  • Shares Outstanding, K 44,520
  • Annual Sales, $ 133,250 K
  • Annual Income, $ 17,140 K
  • 60-Month Beta 1.02
  • Price/Sales 1.84
  • Price/Cash Flow 11.11
  • Price/Book 1.37
Trade KMDA with:

Options Overview

Details
  • Implied Volatility 34.21%
  • Historical Volatility 23.00%
  • IV Percentile 9%
  • IV Rank 7.40%
  • IV High 303.49% on 11/06/20
  • IV Low 12.68% on 05/14/21
  • Put/Call Vol Ratio 16.00
  • Today's Volume 68
  • Volume Avg (30-Day) 198
  • Put/Call OI Ratio 41.67
  • Today's Open Interest 24,367
  • Open Int (30-Day) 22,895

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate 0.05
  • Number of Estimates 2
  • High Estimate 0.06
  • Low Estimate 0.04
  • Prior Year 0.08
  • Growth Rate Est. (year over year) -37.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.34 +3.20%
on 07/27/21
6.00 -8.17%
on 06/29/21
-0.42 (-7.08%)
since 06/28/21
3-Month
5.34 +3.20%
on 07/27/21
6.47 -14.84%
on 06/25/21
-0.61 (-9.97%)
since 04/28/21
52-Week
5.34 +3.20%
on 07/27/21
13.33 -58.66%
on 08/24/20
-3.03 (-35.48%)
since 07/28/20

Most Recent Stories

More News
Gilead (GILD) Inks Deal to Develop Allogeneic Cell Therapies

Gilead's (GILD) wholly owned subsidiary Kite signs partnership deal with Shoreline Biosciences to develop novel cell therapies for cancer.

GILD : 70.06 (+1.64%)
RGEN : 235.28 (+3.93%)
TECH : 476.76 (+0.67%)
KMDA : 5.51 (+1.29%)
Blueprint Medicines (BPMC) Gets FDA Nod for Ayvakyt in SM

The FDA approves Blueprint Medicines' (BPMC) lead drug, Ayvakit, for treating adult patients with advanced systemic mastocytosis.

RGEN : 235.28 (+3.93%)
TECH : 476.76 (+0.67%)
KMDA : 5.51 (+1.29%)
BPMC : 82.91 (+1.48%)
CRISPR (CRSP) Inks Deal for Gene Therapies in Neurological Diseases

CRISPR Therapeutics (CRSP) signs a strategic collaboration with Capsida Biotherapeutics to develop/commercialize gene editing therapies for neurological diseases.

VRTX : 202.24 (-0.30%)
BAYRY : 14.8900 (-0.20%)
KMDA : 5.51 (+1.29%)
CRSP : 119.75 (+1.98%)
Vertex's (VRTX) Trikafta Gets FDA Nod for CF in Children

The FDA approves Vertex's (VRTX) triple combination therapy, Trikafta, for treating cystic fibrosis in children aged between six to 11 years.

VRTX : 202.24 (-0.30%)
RGEN : 235.28 (+3.93%)
TECH : 476.76 (+0.67%)
KMDA : 5.51 (+1.29%)
Arena's (ARNA) Etrasimod Gets FDA's Orphan Drug Tag for EoE

The FDA bestows an Orphan Drug status to Arena's (ARNA) lead pipeline candidate, etrasimod, for the treatment of eosinophilic esophagitis.

ARNA : 63.82 (+4.08%)
RGEN : 235.28 (+3.93%)
TECH : 476.76 (+0.67%)
KMDA : 5.51 (+1.29%)
Alexion's (ALXN) PNH Drug Ultomiris Gets FDA Nod for Kids

The FDA approves Alexion's (ALXN) Ultomiris for the treatment of PNH in children of one month of age and older as well as adolescents.

ALXN : 182.50 (+1.70%)
RGEN : 235.28 (+3.93%)
TECH : 476.76 (+0.67%)
KMDA : 5.51 (+1.29%)
bluebird (BLUE) Resumes SCD & TDT Studies as FDA Lifts Hold

The FDA lifts the clinical hold on bluebird's (BLUE) studies on LentiGlobin for sickle cell disease and betibeglogene autotemcel for transfusion-dependent thalassemia. Shares rise.

RGEN : 235.28 (+3.93%)
TECH : 476.76 (+0.67%)
BLUE : 26.00 (+0.31%)
KMDA : 5.51 (+1.29%)
Kedrion and Kamada Announce FDA Approval of KEDRAB® Label Update, Confirming Safety and Effectiveness in Children

and REHOVOT, , /PRNewswire/ -- and Kamada Ltd. (NASDAQ: KMDA) and (TASE: KMDA), two leading biopharmaceutical companies specialized in plasma-derived protein therapeutics, announced today the U.S. Food...

KMDA : 5.51 (+1.29%)
Kamada (KMDA) Q1 Earnings Top Estimates

Kamada (KMDA) delivered earnings and revenue surprises of 20.00% and -5.86%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

KMDA : 5.51 (+1.29%)
Kamada Reports First Quarter 2021 Financial Results, Recent Achievements and Corporate Development Activities

-- First Quarter 2021 Revenues were $24.9 Million, and Adjusted EBITDA was $3.7 Million

KMDA : 5.51 (+1.29%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Kamada Ltd. is a biopharmaceutical company. It develops, produces and markets therapeutics based on chromatographic purification technology. The company offers bio-therapeutics for specialty proteins, specific immunoglobulins and other prescription medicines. Kamada Ltd. is headquartered in Ness Ziona,...

See More

Key Turning Points

3rd Resistance Point 5.65
2nd Resistance Point 5.60
1st Resistance Point 5.55
Last Price 5.51
1st Support Level 5.45
2nd Support Level 5.40
3rd Support Level 5.35

See More

52-Week High 13.33
Fibonacci 61.8% 10.28
Fibonacci 50% 9.33
Fibonacci 38.2% 8.39
Last Price 5.51
52-Week Low 5.34

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar